Pfizer Inc. (NYSE:PFE) is among the 13 Most Undervalued S&P 500 Stocks to Invest In.
On February 27, 2026, Pfizer Inc. (NYSE:PFE) and Astellas Pharma announced positive Phase 3 EV-304 results for PADCEV, a Nectin-4-directed antibody-drug conjugate, in combination with Keytruda in patients with muscle-invasive bladder cancer eligible for cisplatin-based chemotherapy. Perioperative enfortumab vedotin plus pembrolizumab showed a 47% reduction in the risk of tumor recurrence, progression, or death versus standard of care neoadjuvant gemcitabine and cisplatin. An estimated 79.4% of patients were event-free at two years compared to 66.2% with neoadjuvant chemotherapy.
Overall survival, a key secondary endpoint, reflected a 35% reduced risk of death with the combination. The pathological complete response rate was 55.8% versus 32.5% at surgery. Benefits in event-free survival, overall survival, and pCR were generally consistent across pre-defined subgroups, including age, gender, PD-L1 status, clinical stage, and geographic region. The safety profile was consistent with prior experience, and no new safety signals were observed. Grade greater than or equal to 3 adverse events occurred in 75.7% of patients receiving the combination compared to 67.2% with neoadjuvant chemotherapy. The data were presented in an oral session at the American Society of Clinical Oncology Genitourinary Cancers Symposium in San Francisco and will be discussed with global health authorities for potential regulatory filings.
On February 24, 2026, RBC Capital initiated coverage of Pfizer with an Underperform rating and a $25 price target, citing an “insurmountable” $15B-$20B revenue cliff through 2030 with limited near-term pipeline visibility to offset it. RBC added that while a 6% dividend yield provides downside support above the peer average, it does not offset structural headwinds and a lack of 2026 catalysts.
Pfizer Inc. (NYSE:PFE) discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products globally through its Biopharma, PC1, and Pfizer Ignite segments.
While we acknowledge the potential of PFE as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than PFE and that has a 100x upside potential, check out our report about the cheapest AI stock.
READ NEXT: 12 Best Tech Stocks that Beat Earnings Estimates and 40 Most Popular Stocks Among Hedge Funds Heading Into 2026
Disclosure: None. Follow Insider Monkey on Google News.
